Core Insights - Forian Inc. will announce its third quarter 2024 financial results on November 13, 2024, after market close, followed by a conference call at 4:30 p.m. ET [1] - The company provides data science-driven information and analytics solutions to the healthcare and life sciences industries, and has recently expanded into the financial services sector through the acquisition of Kyber Data Science [3] Company Overview - Forian specializes in data management capabilities and proprietary information solutions aimed at optimizing operational, clinical, and financial performance for clients in healthcare and life sciences, as well as financial services [3] - The company has expertise in acquiring, integrating, normalizing, and commercializing large-scale healthcare data assets, utilizing a comprehensive clinical data lake to generate proprietary insights [3]

NEWTOWN, PA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced it has acquired Kyber Data Science LLC (“Kyber”), a trusted provider of advanced healthcare data analytics and machine learning solutions to the financial services industry, from TD Cowen. This strategic acquisition strengthens Forian’s position in the healthcare information marketplace through the add ...

Core Viewpoint - Forian Inc. reported a quarterly loss of $0.03 per share, matching the Zacks Consensus Estimate, and has not surpassed consensus EPS estimates over the last four quarters [1][2]. Financial Performance - Forian's revenues for the quarter ended June 2024 were $4.78 million, missing the Zacks Consensus Estimate by 9.18%, and down from $4.89 million a year ago [2]. - The company has consistently failed to meet revenue estimates over the past four quarters [2]. Stock Performance - Forian shares have declined approximately 15.6% year-to-date, contrasting with the S&P 500's gain of 13.9% [3]. - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.04 on revenues of $5.88 million, and for the current fiscal year, it is $0.13 on revenues of $22.46 million [7]. - The trend of estimate revisions for Forian is mixed, which may change following the recent earnings report [6]. Industry Context - The Computer - Services industry, to which Forian belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8].

NEWTOWN, PA , Aug. 02, 2024 (GLOBE NEWSWIRE) -- Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, will announce its second quarter 2024 financial results on Wednesday, August 14, 2024, after the close of the market. The Company will host a conference call and webcast at 4:30 p.m. (ET) on August 14, 2024 to discuss the results. To register for the conference call, click here. The webcast will be available live at ...

NEWTOWN, PA , Aug. 02, 2024 (GLOBE NEWSWIRE) -- Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, will announce its second quarter 2024 financial results on Wednesday, August 14, 2024, after the close of the market. The Company will host a conference call and webcast at 4:30 p.m. (ET) on August 14, 2024 to discuss the results. To register for the conference call, click here. The webcast will be available live at ...

This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forwardlooking statements often address expected future business and financial performance and financial condition, which may include GAAP and non-GAAP financial measures, and often contain words such as "expect," "anticipate," "intend," "plan," "believe, ...

Forian Inc. (NASDAQ:FORA) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Max Wygod - Executive Chairman, President and CEO Michael Vesey - CFO Conference Call Participants Operator Greetings, and welcome to Forian Inc.'s First Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only-mode. A question-and-answer session will follow the formal comments and webcast. Participating today from Forian, are Max Wygod, Executive Ch ...

Revenue Performance - Revenues for Q1 2024 were $4,877,378, a slight increase of $6,991 compared to $4,870,387 in Q1 2023, primarily driven by increased sales in the healthcare industry[127]. - The company reported revenue of $4,877,378 for the three months ended March 31, 2024, compared to $4,870,387 in the same period of 2023[145]. Cost and Expenses - Cost of revenues increased to $1,703,357 in Q1 2024, up $451,142 from $1,252,215 in Q1 2023, resulting in a gross profit margin decrease to 65% from 74% year-over-year[128]. - Research and development expenses decreased to $389,889 in Q1 2024, down $141,800 from $531,689 in Q1 2023, reflecting a shift in focus to healthcare analytics[129]. - Sales and marketing expenses were $1,055,141 in Q1 2024, a decrease of $141,051 compared to $1,196,192 in Q1 2023, attributed to lower salaries and scaling expenses[130]. - General and administrative expenses decreased to $3,492,454 in Q1 2024, down $147,372 from $3,639,826 in Q1 2023, mainly due to reduced personnel and consulting costs[132]. Profitability and Loss - The operating loss from continuing operations improved to $(1,772,350) in Q1 2024 from $(2,387,797) in Q1 2023[126]. - Adjusted EBITDA for the three months ended March 31, 2024, was $104,417, an increase of $291,200 compared to a loss of $186,783 for the same period in 2023, primarily due to higher revenues and lower operating expenses[146]. - The company generated a net loss of $1,212,615 for the three months ended March 31, 2024, compared to a net loss of $2,248,799 for the same period in 2023[145]. Cash Flow and Investments - Net cash used in operating activities increased to $2,208,070 for the three months ended March 31, 2024, up by $1,006,293 from $1,201,777 in the same period of 2023[149]. - Net cash used in investing activities increased to $1,774,425 for the three months ended March 31, 2024, compared to $633,003 in the same period of 2023[150]. - Net cash used in financing activities rose to $1,031,363 for the three months ended March 31, 2024, compared to $94,599 in the same period of 2023, primarily due to $950,000 used to redeem convertible securities[152]. - Cash and marketable securities totaled $47,434,985 as of March 31, 2024, with outstanding principal and accrued interest on the Notes amounting to $23,981,788[147]. Strategic Focus and Future Plans - The company plans to continue investing in marketing and sales to build brand awareness and attract new clients[123]. - The company has shifted its focus away from the cannabis industry, following the sale of its subsidiary BioTrack in 2023[118]. - The company expects to continue funding operations and potential future acquisitions through cash flow from operations, available cash, marketable securities, debt financing, and/or additional equity issuances[147]. - The company sold BioTrack for $30,000,000, consisting of $20,000,000 in cash at closing and $10,000,000 in future payments[147]. Non-Recurring Expenses - The company recorded severance expenses of $250,000 related to the resignation of its CEO, which are excluded from Adjusted EBITDA as they are not recurring[145]. - Adjusted EBITDA is used as a performance measure, excluding non-cash expenses like depreciation and stock-based compensation, which helps in evaluating operational performance[135]. - The company recognizes that interest expense from convertible notes of $24,000,000 will recur in future periods, impacting financial performance assessments[140].

Exhibit 99.1 Forian Inc. Announces First Quarter 2024 Financial Results Newtown, PA, May 14, 2024 (GLOBE NEWSWIRE) – via NewMediaWire – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter ended March 31, 2024. "We navigated through the expected tough first quarter environment head-on, and it has not dimmed our optimism for the long- term growth and earning potential of our co ...

NEWTOWN, PA, April 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Forian Inc. (NASDAQ:FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, is deeply saddened to announce the passing of its director, Martin J. Wygod (Marty), on Friday at age 84. Marty was a healthcare entrepreneur, thoroughbred horse breeder and philanthropist. He is the father of Forian Executive Chairman, Chief Executive Officer and President, Max Wygod. Marty was at ...